$PMDI
PSYCHEMEDICS CORP

2013 Q3 Form 10-Q Financial Statement

#000114420413057560 Filed on October 30, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2012 Q3
Revenue $7.055M $6.460M
YoY Change 9.21% 2.22%
Cost Of Revenue $2.879M $2.742M
YoY Change 5.0% 15.7%
Gross Profit $4.176M $3.718M
YoY Change 12.32% -5.63%
Gross Profit Margin 59.19% 57.55%
Selling, General & Admin $2.233M $1.990M
YoY Change 12.25% -0.52%
% of Gross Profit 53.48% 53.51%
Research & Development $203.3K $297.1K
YoY Change -31.58% 112.21%
% of Gross Profit 4.87% 7.99%
Depreciation & Amortization $220.0K $140.0K
YoY Change 57.14% 55.56%
% of Gross Profit 5.27% 3.77%
Operating Expenses $2.437M $2.287M
YoY Change 6.56% 6.86%
Operating Profit $1.739M $1.431M
YoY Change 21.52% -20.5%
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit 0.0% 0.0%
Other Income/Expense, Net
YoY Change
Pretax Income $1.740M $1.431M
YoY Change 21.53% -20.92%
Income Tax $687.6K $552.9K
% Of Pretax Income 39.53% 38.63%
Net Earnings $1.052M $879.0K
YoY Change 19.68% -20.09%
Net Earnings / Revenue 14.91% 13.61%
Basic Earnings Per Share $0.20 $0.17
Diluted Earnings Per Share $0.20 $0.17
COMMON SHARES
Basic Shares Outstanding 5.312M shares 5.272M shares
Diluted Shares Outstanding 5.331M shares 5.290M shares

Balance Sheet

Concept 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.840M $3.660M
YoY Change -22.4% 4.57%
Cash & Equivalents $2.843M $3.663M
Short-Term Investments
Other Short-Term Assets $1.430M $1.540M
YoY Change -7.14% 28.33%
Inventory
Prepaid Expenses
Receivables $5.290M $5.340M
Other Receivables $0.00 $0.00
Total Short-Term Assets $9.557M $10.55M
YoY Change -9.42% -3.21%
LONG-TERM ASSETS
Property, Plant & Equipment $4.954M $3.490M
YoY Change 41.96% 101.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $553.0K $310.0K
YoY Change 78.37% 40.91%
Total Long-Term Assets $5.507M $3.800M
YoY Change 44.93% 94.87%
TOTAL ASSETS
Total Short-Term Assets $9.557M $10.55M
Total Long-Term Assets $5.507M $3.800M
Total Assets $15.06M $14.35M
YoY Change 4.98% 11.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $577.1K $1.270M
YoY Change -54.56% 337.93%
Accrued Expenses $1.598M $980.0K
YoY Change 63.11% -31.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.176M $2.250M
YoY Change -3.31% 30.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.176M $2.250M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.990M $2.730M
YoY Change 9.53% 57.8%
SHAREHOLDERS EQUITY
Retained Earnings -$6.631M
YoY Change
Common Stock $28.79M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $10.08M
YoY Change
Treasury Stock Shares 668.1K shares
Shareholders Equity $12.07M $11.62M
YoY Change
Total Liabilities & Shareholders Equity $15.06M $14.35M
YoY Change 4.98% 11.67%

Cashflow Statement

Concept 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income $1.052M $879.0K
YoY Change 19.68% -20.09%
Depreciation, Depletion And Amortization $220.0K $140.0K
YoY Change 57.14% 55.56%
Cash From Operating Activities $1.700M $1.030M
YoY Change 65.05% -1571.43%
INVESTING ACTIVITIES
Capital Expenditures -$680.0K -$1.290M
YoY Change -47.29% 258.33%
Acquisitions
YoY Change
Other Investing Activities -$130.0K -$40.00K
YoY Change 225.0% -102.03%
Cash From Investing Activities -$800.0K -$1.330M
YoY Change -39.85% -182.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -780.0K -790.0K
YoY Change -1.27% 21.54%
NET CHANGE
Cash From Operating Activities 1.700M 1.030M
Cash From Investing Activities -800.0K -1.330M
Cash From Financing Activities -780.0K -790.0K
Net Change In Cash 120.0K -1.090M
YoY Change -111.01% -222.47%
FREE CASH FLOW
Cash From Operating Activities $1.700M $1.030M
Capital Expenditures -$680.0K -$1.290M
Free Cash Flow $2.380M $2.320M
YoY Change 2.59% 700.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Net Income Loss
NetIncomeLoss
2937271 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
552920 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1827932 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
1052000 USD
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
540097 USD
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
656415 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
679031 USD
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
2286749 USD
us-gaap Operating Expenses
OperatingExpenses
7069062 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1739299 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3075794 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2921880 USD
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
2381845 USD
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
2365730 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-223044 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1900734 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5564233 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3663499 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
-643000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
-1208800 USD
CY2013Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
179915 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
121583 USD
CY2013Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5018365 USD
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4395605 USD
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.005
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.005
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
872521 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
872521 shares
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.005
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.005
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5981896 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5940558 shares
CY2013Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
668130 shares
CY2012Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
668130 shares
CY2013Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
365094 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
9556703 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4954481 USD
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
552955 USD
CY2013Q3 us-gaap Assets
Assets
15064139 USD
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
577081 USD
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1598457 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2175538 USD
CY2013Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
814619 USD
CY2013Q3 us-gaap Liabilities
Liabilities
2990157 USD
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
29910 USD
CY2013Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
28756444 USD
CY2013Q3 us-gaap Treasury Stock Value
TreasuryStockValue
10081789 USD
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6630583 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
12073982 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
91993 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
1442 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1739579 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1431401 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15064139 USD
CY2013Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
7055202 USD
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
20386381 USD
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
19565350 USD
CY2013Q3 us-gaap Cost Of Services
CostOfServices
2879150 USD
CY2012Q3 us-gaap Cost Of Services
CostOfServices
2742072 USD
CY2012Q3 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
6459775 USD
CY2012Q3 us-gaap Gross Profit
GrossProfit
3717703 USD
us-gaap Gross Profit
GrossProfit
11742272 USD
us-gaap Gross Profit
GrossProfit
11486209 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1075133 USD
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
921891 USD
CY2013Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1158355 USD
CY2012Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1067768 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3435257 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3413388 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
203265 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
297090 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
558011 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
2436753 USD
us-gaap Operating Expenses
OperatingExpenses
7014299 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1430954 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
4673210 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
4471910 USD
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
280 USD
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
447 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4765203 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4473352 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
687579 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1766336 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
878481 USD
us-gaap Net Income Loss
NetIncomeLoss
2707016 USD
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
CY2012Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
CY2012Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.51
CY2013Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.15
CY2012Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.15
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.45
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.45
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5312105 shares
CY2012Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5272428 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5301330 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5256240 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5330515 shares
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5289808 shares
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
pmd Proceeds From Repurchase Of Common Stock
ProceedsFromRepurchaseOfCommonStock
-111249 USD
pmd Proceeds From Repurchase Of Common Stock
ProceedsFromRepurchaseOfCommonStock
-94559 USD
pmd Payments For Proceeds From Sale Of Other Assets
PaymentsForProceedsFromSaleOfOtherAssets
227482 USD
pmd Payments For Proceeds From Sale Of Other Assets
PaymentsForProceedsFromSaleOfOtherAssets
81889 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1603314 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1919089 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
20839 USD
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
10000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5314224 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5266237 shares
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
642580 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
419541 USD
us-gaap Share Based Compensation
ShareBasedCompensation
386297 USD
us-gaap Share Based Compensation
ShareBasedCompensation
337078 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
672737 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
852362 USD
pmd Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
-622123 USD
pmd Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
-36183 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-92708 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
304759 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
184916 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-337391 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-155217 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-136180 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3852525 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2478644 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
835735 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1180786 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2472255 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2460289 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
56500 shares
CY2013Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
497506 shares
CY2013Q3 pmd Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Unamortized Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnamortizedFairValue
1200000 USD
pmd Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Unamortized Fair Value Period For Amortization
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnamortizedFairValuePeriodForAmortization
P2Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P1Y6M
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
199838 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
14988 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
7900 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
176950 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
176950 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
0 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.62
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
13.75
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.04
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.04
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
36000 USD
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
36000 USD
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
153000 shares
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
231000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
167000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
264000 shares
CY2013Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
19000 shares
CY2012Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
18000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13000 shares

Files In Submission

Name View Source Status
0001144204-13-057560-index-headers.html Edgar Link pending
0001144204-13-057560-index.html Edgar Link pending
0001144204-13-057560.txt Edgar Link pending
0001144204-13-057560-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
pmd-20130930.xml Edgar Link completed
pmd-20130930.xsd Edgar Link pending
pmd-20130930_cal.xml Edgar Link unprocessable
pmd-20130930_def.xml Edgar Link unprocessable
pmd-20130930_lab.xml Edgar Link unprocessable
pmd-20130930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v357602_10q.htm Edgar Link pending
v357602_ex31-1.htm Edgar Link pending
v357602_ex31-2.htm Edgar Link pending
v357602_ex32-1.htm Edgar Link pending
v357602_ex32-2.htm Edgar Link pending